Literature DB >> 39945

Radioimmunoassay of a basic somatomedin: comparison of various assay techniques and somatomedin levels in various sera.

R M Bala, B Bhaumick.   

Abstract

Purification of a basic somatomedin (SM), with similarity to SM-C and insulin-like growth factor, from human plasma Cohn fraction IV-1 enabled development of a RIA based on this SM.SM antiserum was produced by immunizing rabbits with partially purified SM. This antiserum (final dilution, 1:50,000) specifically bound approximately 40% of added [125I]-SM in this RIA. The RIA sensitivity was 2 x 10(-4) U immunoreactive SM (IRSM). Highly purified SM-C, insulin-like growth factor 1, and our SM revealed parallel and approximately equipotent dose-response curves in this RIA; rat SM and multiplication stimulation activity revealed less cross-reactivity. IRSM was detected in sera of all species tested except fish. Acidification of sera, without subsequent chromatography, before assay permitted measurement of total IRSM with either an equilibrium or nonequilibrium RIA technique. Acidification of serum appears to increase SM-binding capacity while decreasing binding affinity of the 20,000--50,000 mol wt proteins in serum. The mean (+/- SEM) IRSM concentrations in sera from normals and patients with acromegaly, hypopituitarism, GH deficiency before/after treatment, and Laron dwarfism were 1.45 +/- 0.17, 5.49 +/- 0.48, 0.19 +/- 0.07, 0.10 +/- 0.02/0.64 +/- 0.45, and 0.25 +/- 0.11 U/ml, respectively, compared to a pooled normal human serum reference standard which was designated to contain 1 IRSM U/ml. Measurements of total IRSM (bound and free) in serum may not accurately reflect SM bioactivity and will require interpretative caution.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 39945     DOI: 10.1210/jcem-49-5-770

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Somatomedin-C levels related to gestational age, birth weight and day of life.

Authors:  A Cassio; M Capelli; E Cacciari; A Cicognani; P Pirazzoli; F Righetti; D Ballardini; G Natali; S Zucchini; E Martelli
Journal:  Eur J Pediatr       Date:  1986-08       Impact factor: 3.183

2.  Insulin-like growth factors (IGF) I and II in diabetic pregnancy: suppression of normal pregnancy-induced rise of IGF-I.

Authors:  B Bhaumick; A D Danilkewich; R M Bala
Journal:  Diabetologia       Date:  1986-11       Impact factor: 10.122

3.  Somatomedin receptor of human placenta: solubilization, photolabeling, partial purification, and comparison with insulin receptor.

Authors:  B Bhaumick; R M Bala; M D Hollenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

4.  Receptors for insulinlike growth factor I are defective in fibroblasts cultured from a patient with leprechaunism.

Authors:  E E Van Obberghen-Schilling; M M Rechler; J A Romanus; A B Knight; S P Nissley; R E Humbel
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

5.  Amylin increases bone volume but cannot ameliorate diabetic osteopenia.

Authors:  D F Romero; H P Bryer; B Rucinski; J A Isserow; F J Buchinsky; M Cvetkovic; C C Liu; S Epstein
Journal:  Calcif Tissue Int       Date:  1995-01       Impact factor: 4.333

6.  Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia.

Authors:  J Zapf; H Walter; E R Froesch
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

7.  Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma.

Authors:  R C Baxter; J L Martin
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.